The Global Drug sales of Eylea stood at USD 10,673.81 Millions in 2022
The indicator recorded a historical growth (CAGR) of10% between 2019 to 2022 and is expected to grow by ...
GlobalData projects the indicator to decline at a CAGR of...
Aflibercept (Eylea) is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1. Eylea is formulated as an iso-osmotic injection solution for intravitreal route of administration.
Mechanism of Action
Aflibercept (Eylea) is a human, soluble VEGF receptor fusion protein, which binds to all types of VEGF-A as well as the related placental growth factor (PlGF). VEGF (Vascular Endothelial Growth Factor) is a natural growth factor that stimulates the formation of new blood vessels (angiogenesis) and is produced by the body during the growth of tissue and organs, as well as in healing wounds. VEGF is also connected to the abnormal formation of new vessels and their fragility in the eye, which leads to the development of wet AMD. VEGF Trap-Eye specifically blocks these growth factors and therefore has a high potential for efficacy. This prevents the formation of new blood vessels, which plays a major role in the development of wet AMD. Blockage of growth factors (VEGF-A and PIGF) and thus prevention of the formation of new blood vessels (antiangiogenesis).
Eylea Overview
Eylea is marketed for several indications in Metabolic Disorders, and Ophthalmology therapy areas.
Eylea is indicated for treatment of neovascular (wet) age-related macular degeneration (wet AMD) and for the treatment of macular edema following central retinal vein occlusion. It is also indicated for diabetic macular edema (DME) and Diabetic Retinopathy (DR) in Patients with DME, for the treatment of choroidal neovascularization and macular edema secondary to branch retinal vein occlusion (BRVO), for the treatment of visual impairment due to myopic choroidal neovascularization (myopic CNV), and all stages of non-proliferative diabetic retinopathy (DR), and thereby reduce the risk of blindness.
Eylea was first approved in 2011 and is sold globally including the US, the UK, France, Germany, and Japan by several pharma giants including Regeneron Pharmaceuticals Inc, Bayer AG, and Santen Pharmaceutical Co Ltd. Eylea drug sales recorded a mid-single digit Year on Year growth in 2022. Eylea drug sales include the historical sales that are derived from company financial reports, and consensus forecasts are calculated based on company-specific broker reports as well as GlobalData’s proprietary methodology.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward